POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY

Goupille, P.; Behrens, F.; C. Coates, Laura; Gratacós, Jordi; J. Mease, Philip; D. Gladman, Dafna; Nash, Peter; Kavanaugh, Arthur; Martinꝉ, Roland; Bao, W.; Gaillez, Corine; B. McInnes, Iain

doi:10.1136/annrheumdis-2021-eular.1562

Public

POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY

Published in Annals of the Rheumatic Diseases • May 25, 2021

Authors:

P. Goupille

F. Behrens

Laura C. Coates

Abstract

Background: EXCEED (NCT02745080) was the first fully blinded head-to-head trial to evaluate the efficacy and safety of secukinumab (SEC) versus (vs) adalimumab (ADA) monotherapy in patients with active psoriatic arthritis (PsA) with a primary endpoint of American College of Rheumatology (ACR) 20 at ...

Subject

Secukinumab

Medicine

Psoriatic arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!